[6] Merad’s clinical training in Hematology / Oncology and bone marrow transplantation in the Hôpital Saint-Louis and Institut Gustave Roussy in Paris shaped her initial interest in immunotherapy and inspired her move to Stanford to study dendritic cell-based vaccines with Engleman.
Merad's collaboration with Weissman resulted in a series of ontogeny studies that led to the re-writing of textbook chapters describing the origin of macrophages and dendritic cells.
Under Merad's leadership, PrIISM has launched and co-founded with other ISMMS institutes, many programs and centers that support highly productive collaborations between physicians and scientists and enhance synergy between fundamental, translational and clinical research initiatives.
[14] Miram Merad's early studies were among the first to identify the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages.
These studies have revealed the critical contribution of tissue resident macrophages to organ physiology including synaptic pruning, gut peristaltism, fat metabolism and vascular integrity.
In addition to her research program, Merad has published articles on new approaches to cancer immunotherapy clinical trials,[25] how Long COVID can be classified,[26] the importance of immigrants to science in the US[27] and written about her experiences as a mother and a scientist.